Histological and behavioral protection by (-)-nicotine against quinolinic acid-induced neurodegeneration in the hippocampus

Neurobiology of Learning and Memory

Volumn 69, Issue 1, 1998, Pages 46-64

  O'Neill, Alyssa B ^a   Morgan, Sherry J ^a   Brioni, Jorge D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Hippocampus; Learning; Memory; Nicotine; Quinolinic acid

Indexed keywords

NICOTINE TARTRATE; NICOTINIC RECEPTOR; QUINOLINIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; GRANULE CELL; HIPPOCAMPUS; HISTOLOGY; LEARNING; MALE; MEMORY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PYRAMIDAL NERVE CELL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031926849     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1006/nlme.1997.3803     Document Type: Article

References (32)

1. Akaike, A., Tamura, Y., Yokaota, T., Shimohama, S., & Kimura, J. (1994). Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Research, 644, 181-187.
2. Arneric, S., Sullivan, J., & Williams, M. (1995). Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics. In F. Bloom & D. Kupfer (Eds.), Psychopharmacology: Fourth generation of progress (pp. 95-110). New York: Raven Press.
3. Beninger, R. J., Wirsching, B. A., Jhamandas, K., Boegman, R. J., & El-Defrawy, S. R. (1986). Effects of altered cholinergic function on working and reference memory in the rat. Canadian Journal Physiology and Pharmacology, 64, 376-382.
4. Block, F., Kunkel, M., & Schwarz, M. (1993). Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neuroscience Letters, 149, 126-128.
5. Brioni, J. D., Decker, M. W., Gamboa, L. P., Izquierdo, I., & McGaugh, J. L. (1990). Muscimol injections in the medial septum impair spatial learning. Brain Research, 522, 227-234.
6. Brioni, J. D., Decker, M. W., Sullivan, J. P., & Arneric, S. P. (1996). The pharmacology of (-)-nicotine and novel cholinergic channel activators. Advances in Pharmacology, 37, 153-214.
7. Brioni, J. D., Morgan, S. J., O'Neill, A. B., Sykora, T. M., Postl, S. P., Pan, J. B., Sullivan, J. P., & Arneric, S. P. (1996). "In vivo" profile of novel nicotinic ligands with CNS selectivity. Medicinal Chemistry Research, 6, 487-510.
8. Chen, Y., Ogren, S., Bjelke, B., Bolme, P., Eneroth, P., Gross, J., Loidl, F., Herrera-Marschitz, M., & Anderson, K. (1995). Nicotine treatment counteracts perinatal asphyxia-induced changes in the mesostriatal-limbic dopamine systems and in motor behaviour in the four-week-old male rat. Neuroscience, 68, 531-538.
9. Decker, M. W., Brioni, J. D., Sullivan, J. P., Buckley, M. J., Radek, R. J., Raskiewickz, J. L., Kang, C. H., Kim, D. J. B., Giardina, W. J., Williams, M., & Arneric, S. P. (1994). ABT 418: A novel cholinergic ligand with cognition enhancing and anxiolytic activities. II. In vivo characterization. Journal of Pharmacology and Experimental Therapeutics, 270, 319-328.
10. Donnelly-Roberts, D., Xue, I., Arneric, S., & Sullivan, J. (1996). In vitro neuroprotective properties of a novel cholinergic channel activator (ChCA), ABT-418. Brain Research, 719, 36-44.
11. Foster, A. C., & Woodruff, G. N. (1988). Neuroprotective effects of MK-801 "in vivo": Selectivity and evidence for delayed degeneration mediated by NMDA receptor activation. Journal of Neuroscience, 8, 4745-4754.
12. Fuxe, K., Rosen, L., Lippoldt, A., Andbjer, B., Hasselrot, U., Finman, U., & Agnati, L. (1994). Chronic continuous infusion of nicotine increases the dissapearance of choline acetyltransferase immunoreactivity in the cholinergic cell bodies of the medial septal nucleus following a partial unilateral transection of the fimbria fornix. Clinical Investigations, 72, 262-268.
13. Heyes, M. P., Saito, K., Major, E. O., Milstien, S., Markey, S. P., & Vickers, J. H. (1993). A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Brain, 116, 1425-1450.
14. Janson, A., Fuxe, K., Agnati, L., Katayama, I., Harfstrand, A., Anderson, K., & Goldstein, M. (1988). Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-inmunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Research, 455, 332-345.
15. Kodsi, M. H., & Swerdlow, N. R. (1994). Quinolinic acid lesions of the ventral striatum reduce sensorimotor gating of acoustic startle in rats. Brain Research, 643, 59-65.
16. Levin, E. D. (1992). Nicotinic systems and cognitive function. Psychopharmacology, 108, 417-431.
17. Lipton, S. A., & Rosenberg, P. A. (1994). Excitatory amino acids as a final common pathway for neurological disorders. New England Journal of Medicine, 330, 613-622.
18. Marin, P., Maus, M., Desagher, S., Glowinski, J., & Premont, J. (1994). Nicotine protects cultured striatal neurons against N-methyl-D-aspartate receptor-mediated neurotoxicity. NeuroReport, 5, 1977-1980.
19. Martin, E., Panickar, K., King, M., Deyrup, M., Hunter, B., Wang, G., & Meyer, E. (1994). Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons. Drug Development Research, 31, 135-141.
20. Morris, R. (1984). Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods, 11, 47-60.
21. O'Neill, A. B., Morgan, S. J., Sykora, T., Postl, S., & Brioni, J. D. (1996). Hippocampal neurodegeneration induced by quinolinic acid: Histological and behavioral protection by nicotine. Society for Neuroscience Abstracts, 22, 834.9.
22. Owman, C., Fuxe, K., Jason, A., & Kahrstrom, J. (1989). Studies of protective actions of nicotine on neuronal and vascular functions in rats: Comparison between sympathetic noradrenergic and mesostriatal dopaminergic fiber system, and the effect of a dopamine agonist. Progress in Brain Research, 79, 267-276.
23. Perkins, M. N., & Stone, T. W. (1983). Quinolinic acid: Regional variations in neuronal sensitivity. Brain Research, 259, 172-176.
24. Reinhard, J. F., Erickson, J. B., & Flanagan, E. M. (1994). Quinolinic acid in neurological disease: Opportunities for novel drug discovery. Advances in Pharmacology, 30, 85-127.
25. Schwarcz, R., & Kohler, C. (1983). Differential vulnerability of central neurons of the rat to quinolinic acid. Neuroscience Letters, 38, 85-90.
26. Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1982). Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science, 219, 316-318.
27. 3H]GABA uptake in nucleus basalis lesioned rats. Brain Research, 624, 295-298.
28. Stone, T. W. (1993). Neuropharmacology of quinolinic and kynurenic acid. Pharmacological Reviews, 45, 309-379.
29. Stone, W., & Perkins, M. N. (1981). Quinolinic acid: A potent endogenous excitant at aminoacid receptors in CNS. European Journal of Pharmacology, 72, 411-412.
30. Vecsei, L., & Beal, M. F. (1991). Comparative behavioral and neurochemical studies with striatal kainic acid or quinolinic acid lesioned rats. Pharmacology Biochemistry and Behavior, 39, 473-478.
31. Winn, P., Stone, T. W., Latimer, M., Hastings, M. H., & Clark, A. J. M. (1991). A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phophonovaleric acid and kynurenic acid in the rat. British Journal of Pharmacology, 102, 904-908.
32. Wirsching, B. A., Beninger, R. J., Jhamandas, K., Boegman, R. J., & Bialik, M. (1989). Kynurenic acid protects against the neurochemical and behavioral effects of unilateral quinolinic acid injections into the nucleus basalis of rats. Behavioral Neuroscience, 103, 90-97.